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Abstract Ursolic acid (UA), a pentacyclic triterpene acid, is
reported to have anti-tumor activities; however, the mechanism
underlying its anti-tumorigenic effects is poorly understood. To
further determine the mechanism of UA, we investigated the
effects of UA on the release of nitric oxide (NO) and tumor
necrosis factor-K (TNF-K), and on the level of inducible nitric
oxide synthase (iNOS) and TNF-K gene expression in mouse
resting macrophages. We found that UA elicited a dose-
dependent increase in NO and TNF-K production, and the level
of iNOS and TNF-K mRNA. Transient expression and
electrophoretic mobility shift assays with nuclear factor-UB
(NF-UB) binding sites revealed that the increased level of iNOS
mRNA and TNF-K mRNA induced by UA were mediated by the
NF-UB transcription factor complex. These results demonstrate
that UA stimulates NO and TNF-K release and is able to
upregulate iNOS and TNF-K expression through NF-UB
transactivation in the resting macrophages. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Macrophages play a signi¢cant role in host defense mech-
anisms. When activated, they inhibit the growth of a wide
variety of tumor cells and microorganisms. Nitric oxide
(NO), a free-radical gas, is synthesized by inducible nitric
oxide synthase (iNOS) [1,2] and mediates diverse functions,
including vasodilatation, neurotransmission, the inhibition of
platelet aggregation, immunoresponses, and the inhibition of
extracellular matrix production [3]. NO has been identi¢ed as
the major e¡ector molecule involved in the destruction of
tumor cells by activated macrophages [4,5]. Moreover, the
involvement of NO during non-speci¢c host defense, macro-
phage-mediated killing, and the inhibition of the proliferation
of microorganisms and tumor cells both in vitro and in vivo
have been previously demonstrated [6,7]. Such NO-mediated
tumoricidal activity is induced by DNA damage and leads to
apoptotic cell death [8]. The administration of NOS inhibitors
to mice has been found to promote the growth of several
transplantable tumors [7], and melanoma cells transfected
with iNOS cDNA were found not proliferate and metastasize
well [9]. Tumor necrosis factor-K (TNF-K) is produced by
activated macrophages, ¢broblasts, and many di¡erent types
of cells. TNF-K has also been recognized and well character-
ized as an important host defense molecule that a¡ects tumor
cells [4,10^12]. In macrophages, nuclear factor UB (NF-UB) in
cooperation with other transcription factors was found to
coordinate the expression of genes encoding iNOS. Moreover,
NF-UB plays a critical role in the activation of immune cells
by upregulating the expression of many cytokines essential for
immune response [13].
Herbal medicines derived from plant extracts are being in-
creasingly utilized to treat a wide variety of clinical diseases,
with relatively little knowledge of their modes of action. There
is a growing interest in the elucidation of the biological roles
of triterpenoid compounds, the major components of some
traditional medicinal plants [14,15], in terms of hepatoprotec-
tory, analgesic, anti-tumor, anti-in£ammatory and immuno-
modulatory e¡ects. Ursolic acid (UA; 3L-hydroxy-urs-12-en-
28-oic acid), is a triterpenoid compound, which is present in
many kinds of medicinal plants, such as Eriobotrya japonica,
Rosmarinus o⁄cinalis, and Glechoma hederaceae [16^18], in
the form of free acid or as aglycones of triterpenoid saponins
[14]. It has been reported that UA produce a wide variety of
anti-tumor activity, including inhibition of tumorigenesis [18]
and tumor promotion [16,17], and the induction of tumor cell
di¡erentiation [19], an anti-angiogenic e¡ect [20], and anti-
invasive activity in human ¢brosarcoma cells [21]. UA also
induces growth inhibition at the G1 phase of the cell cycle
and apoptosis in certain cancer cell systems [22,23]. However,
the mechanisms by which UA induces such cellular e¡ects are
poorly understood. To further characterize the mechanisms
involved in UA-mediated anti-tumor e¡ects, we tested the
hypothesis that UA derives its anti-tumor e¡ect by the release
of NO from macrophages. We investigated the e¡ects of UA
on the release of NO and TNF-K, and on the level of iNOS
and TNF-K gene expression in mouse macrophages.
2. Materials and methods
2.1. Chemicals
Chemicals and cell culture materials were obtained from the follow-
ing sources: UA, Escherichia coli 0111:B4 lipopolysaccharide (LPS)
and Polymyxin B sulfate (Sigma); MTT-based colorimetric assay kit
(Roche); LipofectAMINE Plus, RPMI 1640, fetal bovine serum, and
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penicillin^streptomycin solution (Life Technologies); pGL3-4KB-Luc
and the luciferase assay system (Promega); pCMV-L-gal (Clonetech);
other chemicals were of the highest commercial grade available.
2.2. Animals
Speci¢c pathogen free-BALB/C mice (female, 5^7 weeks old) were
obtained from KRIBB (South Korea). Mice were housed under nor-
mal laboratory conditions, i.e. at 21^24‡C and 40^60% relative hu-
midity, under a 12 h light/dark cycle with free access to standard
rodent food and water.
2.3. Preparation of peritoneal macrophages and cell cultures
Peritoneal macrophages were isolated from mice and cultured as
described previously [24]. RAW 264.7 cells, mouse macrophage cell
line, were obtained from the American Type Culture Collection (Be-
thesda, MD, USA), and grown in RPMI 1640 supplemented with 10%
fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100
Wg/ml streptomycin at 37‡C in a 5% CO2 humidi¢ed incubator. UA
was dissolved in dimethylsulfoxide and added directly to the culture
media. Control cells were treated only with solvents, the ¢nal concen-
tration of which never exceeded 0.1% and this concentration did not
show any e¡ect on the assay systems.
2.4. Cell viability
Cell viability was assessed using a MTT-based colorimetric assay kit
(Roche), according to the manufacturer’s instructions.
2.5. Nitrite assay
Peritoneal macrophages (2U105 cells/ml) or RAW 264.7 cells
(5U105 cells/ml) were cultured in 48-well plates. After incubating
for 24 h, NO synthesis was determined by assaying the culture super-
natants for nitrite, the stable reaction product of NO with molecular
oxygen, using Ellman’s reagent as described previously [24].
2.6. Immunoassay of TNF-K
Peritoneal macrophages or RAW 264.7 cells were cultured at a
density of 2U106 cells/ml for 6 h in 24-well plates. TNF-K production
was quanti¢ed by sandwich immunoassays as described previously
[24]. Recombinant murine TNF-K was used as a standard.
2.7. Endotoxin Assay
An E-Toxate test (Limulus Amebocyte Lysate; Sigma) was used to
assay UA for the presence of Gram-negative bacterial endotoxin
(LPS), according to the manufacturer’s instructions.
2.8. RNA preparation and iNOS mRNA analysis by reverse
transcription-polymerase chain reaction (RT-PCR)
RAW 264.7 cells were cultured with UA at a density of 1U106 cells/
ml for 6 h. Total cellular RNA was isolated by the acidic phenol
extraction procedure of Chomczynski and Sacchi [25]. cDNA synthe-
sis, semiquantitative RT-PCR for iNOS, TNF-K, and L-actin mRNA,
and the analysis of results were performed as described previously
[24]. cDNA was synthesized from 2 Wg of total RNA using an Omni-
script RT-PCR kit as instructed. A cycle number that fell within the
exponential range of response for iNOS (754 bp, 35 cycles), TNF-K
(692 bp, 35 cycles), and L-actin (153 bp, 17 cycles) was used. PCR
reactions were electrophoresed through a 2.5% agarose gel and visu-
alized by ethidium bromide staining and UV irradiation. Gel images
were captured on a Gel Doc Image Analysis System (Kodak), and the
yield of PCR products was normalized to L-actin after quantitative
estimation using NIH Image software (Bethesda, MD, USA). The
relative expression levels were arbitrarily set at 1.0 in the control
group.
2.9. Transfection and luciferase and L-galactosidase assays
RAW 264.7 cells (5U105 cells/ml) were plated in each well of a 12-
well plate, and 12 h later, transiently co-transfected with the plasmids
pGL3-4UB-Luc and pCMV-L-gal using LipofectAMINE Plus accord-
ing to the manufacturer’s protocol. Brie£y, the transfection mixture
containing 0.5 Wg of pGL3-4UB-Luc and 0.2 Wg of pCMV-L-gal was
mixed with the LipofectAMINE Plus reagent and added to cells. After
18 h, cells were treated with UA or LPS for 12 h, and then lysed.
Luciferase and L-galactosidase activity were determined as described
previously [24]. Luciferase activity was normalized using L-galactosi-
dase activity and was expressed relative to the control activity.
2.10. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared as previously described [26]. Two
double-stranded deoxyoligonucleotides containing the NF-UB binding
site (5P-GGGGACTTTCC-3P) [2] were end-labeled with [Q-32P]dATP.
Nuclear extracts (5 Wg) were incubated with 2 Wg of poly (dI-dC) and
the 32P-labeled DNA probe in binding bu¡er (100 mM NaCl, 30 mM
HEPES, 1.5 mM MgCl2, 0.3 mM EDTA, 10% glycerol, 1 mM dithio-
threitol, 1 mM phenylmethylsulfonyl £uoride, 1 Wg/ml concentration
each of aprotinin and leupeptin) for 10 min on ice. DNA binding was
separated from the free probe using a 4.8% polyacrylamide gel in
0.5UTBE bu¡er (44.5 mM Tris, 44.5 mM boric acid, and 1 mM
EDTA). Following electrophoresis, the gel was dried and subjected
to autoradiography.
2.11. Statistical analysis
All experiments were repeated at least three times. The Student’s
t-test was used to assess the statistical signi¢cance of di¡erences. A
con¢dence level of 6 0.05 was considered signi¢cant.
3. Results and discussion
Since UA is known to have anti-tumor activity [16^23], we
investigated the e¡ects of UA on the release of NO and
TNF-K, and its e¡ects on the level of iNOS and TNF-K
gene expression in mouse macrophages. Our ¢ndings indicate
that in macrophages, UA stimulates NO and TNF-K release
and is able to upregulate iNOS and TNF-K expression
through NF-UB transactivation. UA-induced NO production
was assessed using the Griess reaction, and the basal level of
NO in untreated peritoneal macrophages was found to be less
than 2 WM (Table 1). Moreover, UA showed a signi¢cant
e¡ect on nitrite production from 1 WM. Upon UA stimula-
tion, nitrite release by peritoneal macrophages increased in a
dose-dependent manner in the range of 1^10 WM (Table 1),
and showed a cytotoxic action toward macrophages at con-
centrations over 30 WM (data not shown). In addition, the
potent macrophage activator LPS increased nitrite synthesis
Table 1
E¡ects of UA on NO and TNF-K secretion
Treatmenta Macrophages RAW 264.7
Nitrite (WM)b TNF-K (ng/ml)c Nitrite (WM)b TNF-K (ng/ml)c
Control 1.61 þ 0.21 0.65 þ 0.11 2.15 þ 0.33 0.73 þ 0.13
UA 1 WM 3.35 þ 0.43* 2.11 þ 0.32* 6.01 þ 6.43* 2.82 þ 0.41*
UA 5 WM 7.65 þ 0.83* 5.21 þ 0.63* 22.42 þ 3.17* 6.51 þ 0.82*
UA 10 WM 12.11 þ 1.36* 9.33 þ 1.23* 43.91 þ 5.21* 11.05 þ 1.65*
LPS 0.5 Wg/ml 13.52 þ 1.44* 11.56 þ 1.31* 52.31 þ 6.13* 14.52 þ 1.64*
Values are expressed as mean þ S.D. of three individual experiments, performed in triplicate. *P6 0.05, signi¢cantly di¡erent from the control
aMurine peritoneal macrophages (2U105 cells/ml for nitrite assay, and 2U106 cells/ml for TNF-K immunoassay) or RAW 264.7 cells (5U105
cells/ml for nitrite assay, and 2U106 cells/ml for TNF-K immunoassay) were cultured with the indicated concentrations of UA or LPS.
bSupernatants were harvested 24 h later and assayed for NO.
cSupernatants were harvested 6 h later and assayed for TNF-K.
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compared to the control. Consistent with these ¢ndings, UA
also induced nitrite generation in a dose-dependent manner in
RAW 264.7 cells (Table 1). As found in the NO assay, upon
UA stimulation, TNF-K secretions increased in a dose-depen-
dent manner in peritoneal macrophages and RAW 264.7 cells
(Table 1). These results suggest that the secretion of NO and
TNF-K is regulated by the same mechanism, or that TNF-K,
which is produced ¢rst, induces NO secretion via an autocrine
or paracrine system. TNF-K is the ¢rst compound of the
TNF-K and NO series to be secreted by macrophages [27].
Thus, TNF-K is involved in the early phase of the cytokine
cascade and induces NO production.
NO is involved in the killing and proliferative inhibition of
microorganisms, the destruction of tumor cells by activated
macrophages, and is a component of the non-speci¢c host
defense [5^9,28,29]. Furthermore, it has demonstrated that
murine macrophages stimulated by TNF-K [5] produce NO
via the expression of the iNOS gene, and it is believed that
the reactive nitrogen intermediates so induced play a signi¢-
cant role in tumoricidal and microbiocidal activities [5].
TNF-K, an endogenous factor with tumor-selective cytotoxic-
ity, has been recognized as an important host defense mole-
cule that a¡ects tumor cells. Moreover, the induction of NO
and TNF-K production and gene expression by activated
macrophages can lead to cytostatic and cytotoxic e¡ects on
malignant cells [4,6,10^12,24]. Because of the pivotal role of
NO and TNF-K in the anti-microbial and tumoricidal activ-
ities of macrophages, signi¢cant e¡ort has been focused on
developing therapeutic agents that regulate NO and TNF-K
Table 2
E¡ects of polymyxin B on NO and TNF-K secretion by UA and
LPS
Treatmenta Nitrite (WM)b TNF-K (ng/ml)c
Control 2.17 þ 0.32* 0.67 þ 0.12*
UA 47.31 þ 5.61 10.05 þ 1.34
UA+polymyxin B 48.95 þ 5.37 11.51 þ 1.46
LPS 55.74 þ 6.12 13.52 þ 1.85
LPS+polymyxin B 14.82 þ 1.72* 5.37 þ 0.07*
*P6 0.05, signi¢cantly di¡erent from the LPS and UA
aRAW 264.7 cells (5U105 cells/ml for nitrite assay, and 2U106
cells/ml for TNF-K immunoassay) cultured with UA (10 WM) or
LPS (0.5 Wg/ml), in the presence or absence of polymyxin B (10 Wg/
ml).
bSupernatants were harvested 24 h later and assayed for NO.
cSupernatants were harvested 6 h later and assayed for TNF-K. Val-
ues are expressed as mean þ S.D. of three individual experiments,
performed in triplicate.
Fig. 1. E¡ects of UA on iNOS and TNF-K mRNA expression.
RAW 264.7 cells (1U106 cells/ml) were cultured for 6 h in the pres-
ence of media alone, with the indicated concentrations of UA, or
with LPS (0.5 Wg/ml). Cells were lysed and total RNA was prepared
for the RT-PCR analysis of gene expression. PCR ampli¢cation of
the housekeeping gene, L-actin, was performed for each sample. The
PCR ampli¢cation products were electrophoresed in 2.5% agarose
gel and stained with ethidium bromide. One of three representative
experiments is shown. The ratio of the RT-PCR products of iNOS
or TNF-K to L-actin was calculated. Induction-fold is represented as
a mean þ S.D. of three separate experiments. *P6 0.05, signi¢cantly
di¡erent from the control.
Fig. 2. E¡ects of UA on NF-UB-dependent luciferase gene expres-
sion. RAW 264.7 cells (5U105 cells/ml) were transiently co-trans-
fected with pGL3-4UB-Luc and pCMV-L-gal. After 18 h, cells were
treated with the indicated concentrations of UA or LPS (0.5 Wg/ml)
for 12 h. Cells were then harvested, and luciferase and L-galactosi-
dase activities determined. Luciferase activities were expressed rela-
tive to the control. Each bar shows the mean þ S.D. of three inde-
pendent experiments, performed in triplicate. *P6 0.05, signi¢cantly
di¡erent from the control.
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production [30]. Based on these results and the relationship
between nitrite and the cytolytic function of macrophages
against a variety of tumors [7,28], we suggest that the anti-
tumor e¡ect of UA might be mediated in part through the
activation of NO and TNF-K secretion.
Macrophages can be induced to produce NO and TNF-K
by LPS, endotoxins, or cytokines [28]. To con¢rm that the
ability of UA to induce NO and TNF-K could not be attrib-
uted to LPS contamination, the UA was tested for the pres-
ence of contaminating LPS using the Limulus amoebocyte
lysate test. The level of LPS in UA was below the detection
limit, which was less than 12.5 pg/ml (data not shown). Poly-
myxin B sulfate has been used previously as a LPS inhibitor in
macrophage cultures [31], and although UA contained no
detectable activity in the Limulus amoebocyte lysate assay,
we checked for possible LPS contamination in UA, by adding
polymyxin B to cell cultures treated with UA. As shown in
Table 2, polymyxin B e¡ectively inhibited the NO and TNF-K
secretion induced by LPS, but had no e¡ect on the UA. This
result demonstrated that the production of NO and TNF-K by
UA was unlikely to have resulted from LPS contamination in
the UA.
As stated above, UA induced macrophage secretion of NO
and TNF-K. In order to determine whether UA regulates NO
and TNF-K secretion at the mRNA level, a RT-PCR assay
was conducted. LPS was used as a positive control. Consistent
with the results obtained from the NO assay, iNOS mRNA
levels were markedly increased by UA treatment (Fig. 1). This
result indicates that UA upregulated, in a dose-dependent
manner, NO accumulation in macrophages. Therefore, we
believe that increased NO production by UA is regulated
through transcriptional activation. Under the same treatment
conditions, the TNF-K gene expression marker of macrophage
activation was also examined, and similarly, UA was found to
signi¢cantly enhance the expression levels of the TNF-K gene
(Fig. 1). This result is consisted with that obtained from the
immunoassay of TNF-K in macrophages, and indicates that
the UA also upregulates TNF-K accumulation in a dose-de-
pendent manner.
NF-UB is a member of the Rel family and is a common
regulatory element in the promoter region of many cytokines.
In activated macrophages, NF-UB in synergy with other tran-
scriptional activators plays a central role in coordinating the
expression of genes encoding iNOS, TNF-K, and interleukin-1
(IL)-1 [13]. To further investigate the role of UA on iNOS and
TNF-K gene expression, the e¡ect of UA on NF-UB-depen-
dent gene expression was assessed using the luciferase reporter
gene assay. RAW 264.7 cells were transiently transfected with
a plasmid containing four copies of the NF-UB binding sites
and the luciferase activities were measured. LPS, an immuno-
stimulatory agent, was used as a positive control. Nearly a six-
fold increase in the luciferase activity was observed compared
to the unstimulated control cells when cells were stimulated
with LPS. Consistent with NO production and iNOS mRNA
measurement, UA also signi¢cantly increased NF-UB-depen-
dent luciferase activities in a dose-dependent manner (Fig.
2). To further investigate the putative mechanism by which
UA activates iNOS, the e¡ects of UA on the activation of a
family of transcription factors was monitored by gel shift
assay. NF-UB binding activity was examined in light of its
critical role in the regulation of iNOS and TNF-K. EMSA
demonstrated that UA induced a marked increase in NF-UB
binding to its conserved site that could be visualized by a
distinct band (Fig. 3). These results indicate that the upregu-
lation of the iNOS and TNF-K gene by UA is mediated by the
transactivation of NF-UB. Although we demonstrated the up-
regulatory ability of UA on iNOS and TNF-K expression in
macrophages, the mechanism by which UA stimulated iNOS
and TNF-K expression in macrophages remains unknown,
such as the activation of Raf-1 and MAP kinases [32]. Addi-
tional studies are needed to answer these questions and to
elucidate the mechanisms involved.
Previously, several studies have shown that the treatment of
UA or synthetic oleananes leads to reduction of LPS- or
PMA(phorbol 12-Myristate 13-acetate)-inducible NO produc-
tion, and iNOS and inducible cyclooxygenase expression
through inhibition of NF-UB activation [33,34]. We also con-
¢rmed that UA decreased LPS-inducible NO production and
iNOS expression (data not shown). In the present study, how-
ever, we found that the treatment of UA in the absence of
LPS caused enhancement of NO and TNF-K production, as
well as iNOS and TNF-K mRNA induction via transactiva-
tion of NF-UB. These results have provided evidence that UA
may have dual e¡ects on the iNOS expression depending on
the resting or stimulating state of macrophages. UA is able to
induce the basal (intrinsic) level of NO and TNF-K produc-
tion even though UA cause the reduction of LPS-inducible
NO production and iNOS expression. iNOS-derived NO has
been found to inhibit the DNA binding activities of cysteine-
rich transcription factors through reactive nitrogen oxide spe-
cies [35]. For example, NO inhibits the DNA binding activity
of NF-UB, AP-1, c-Myb, SP1, and EGR-1 [35^39]. Each of
these contains a cysteine residue in or near their DNA binding
Fig. 3. E¡ects of UA on NF-UB-binding. RAW 264.7 cells were
treated with LPS (0.5 Wg/ml) or UA for 1 h. Nuclear extracts were
isolated and used in an EMSA with 32P-labeled NF-UB oligonucleo-
tide as a probe, as described in Section 2. The arrow indicates the
NF-UB binding complex. Cold: 200-fold molar excess of non-labeled
NF-UB probe. One of three representative experiments is shown.
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region, which probably represents the target site for S-nitro-
sation. Therefore, there is a possibility that the blocking of
LPS-induced NF-UB activation by UA treatment [33] might
be mediated in part through the inhibition of DNA binding
activity of NF-UB by UA-induced NO. The biological signi¢-
cance of di¡erence e¡ects of UA on the NO production be-
tween the basal and LPS-inducible state need to be deter-
mined.
The cytotoxicity of tumor cells is dependent on the activa-
tion of macrophages, which is strongly correlated with the
expression patterns of several cytokine mediators. Marcinkie-
wicz et al. [40] demonstrated that the increasing NO levels
enhance the release of TNF-K and reactive oxygen species.
This e¡ect may be due to both an increased generation of
the superoxide anion, and the preferential formation of per-
oxynitrite, which can be formed by direct reaction between
NO and the superoxide radical ; both have powerful cytotoxic
properties [41]. The decomposition product of peroxynitrite
and the hydroxy radical is believed to be the most toxic oxy-
gen molecule in vivo [42]. NO and TNF-K were investigated in
the current study to con¢rm the possibility that UA might be
an immunostimulator, and UA was found to elicit NO and
TNF-K production. This result supports the possibility that
NO and TNF-K induction by UA may contribute in vivo to
its immunomodulatory and anti-tumoricidal activities. Biolog-
ical response modi¢ers are widely used in cancer immunoche-
motherapy to potentiate therapeutic e⁄cacy or to alleviate the
toxicity of cytotoxic anti-cancer agents. It is interesting that
UA can upregulate iNOS expression in macrophages. NO is
known to act as a powerful inducer of apoptosis through
upregulation of the proapoptotic proteins, such as P53 and
Bax [35]. Thus, the e¡ect of UA on the cell cycle and apopto-
sis in cancer cells [22,23] may be mediated in enhanced NO
production. The use of UA has been recommended for skin
cancer therapy in Japan [43]. Further studies on UA will be
needed to prove its clinical usefulness in cancer therapy and
its e¡ectiveness in other diseases. In order to investigate the
overall anti-tumor e¡ect of UA, a study on the in vivo in-
duction of gene expression and the production of immuno-
modulatory cytokines in mice is underway in our laboratory.
However, the exact mechanism underlying UA-induced NO
production and release remains to be elucidated.
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